Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

T M Kim,M Taszner,S Novelli,S-G Cho,J C Villasboas,M Merli,A Jiménez-Ubieto,B Tessoulin,L M Poon,D Tucker,J Walewski,S Yi,Y Song,G Chong,E Bachy,S Guidez,A Alonso,D Jagadeesh,W Zhang,L Magnano,E Iskierka-Jażdżewska,M Tani,B Shen,A Uppala,M Zhu,S Shariff,J Brouwer-Visser,A Chaudhry,H Mohamed,S Ambati,S Luminari,ELM-2 Investigators
DOI: https://doi.org/10.1016/j.annonc.2024.08.2239
2024-08-13
Abstract:Background: Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple subtypes of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Patients and methods: This phase II study (ELM-2; NCT03888105) evaluated odronextamab in patients with R/R follicular lymphoma (FL) after ≥2 lines of systemic therapy. Patients received intravenous odronextamab in 21-day cycles, with step-up dosing in Cycle 1 to help mitigate the risk of cytokine release syndrome (CRS), until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by independent central review. Results: Among 128 patients evaluated, 95% completed Cycle 1, and 85% completed ≥4 cycles. At 20.1 months' efficacy follow-up, ORR was 80.0% and complete response rate was 73.4%. Median duration of complete response was 25.1 months. Median progression-free survival was 20.7 months, and median overall survival was not reached. Discontinuation of odronextamab due to adverse events (AEs) occurred in 16% of patients. The most common treatment-emergent AEs were CRS (56%; grade ≥3 1.7% [1/60] with 0.7/4/20 mg step-up), neutropenia (39%), and pyrexia (38%). Conclusions: Odronextamab achieved high complete response rates with generally manageable safety in patients with heavily pretreated R/R FL.
What problem does this paper attempt to address?